Ex-Ax­o­vant crew at Arvelle ups Se­ries A haul, de­ploy­ing $200M-plus to com­mer­cial­ize epilep­sy drug in Eu­rope

One of the char­ac­ter­is­tic fea­tures of the sprawl­ing biotech group Vivek Ra­maswamy has built at Roivant is its abil­i­ty to whip up big-mon­ey fi­nanc­ing deals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.